Wipro Limited announced a partnership with Transcell Oncologics to transform vaccine safety assessment using augmented intelligence (AI).
In this partnership, Transcell’s innovative stem cell technology will be combined with Wipro HOLMES’s advanced augmented intelligence capabilities to improve the safety of global vaccine immunization programs. In addition, it will expand the Wipro HOLMES solutions available to life science organizations.
The solution uses AI for drug repurposing and a Messenger Ribonucleic Acid (mRNA)based platform for bio-defense. In addition, it enables the testing of new vaccines by using augmented intelligence to stem cell research and measuring safety and potency.
This solution is the first one in a series of next-gen solutions that the collaboration will offer to determine the safety and efficiency of a wide range of products from vaccines to prescription medications, cosmetics, and others.
As of now, vaccine safety assessment mostly includes testing on animals to measure adverse impacts. However, with the help of Wipro HOLMES, researchers and biopharma companies have a new and fully viable solution and alternative. It can also be combined into any existing workflow, including quality control tests in vaccine production, batch-wise release, and other safety evaluation assays.
The Bengaluru-headquartered IT company issued a statement; it said: “By applying Augmented Intelligence to the vaccine development process, this solution is capable of predicting adverse neurovirulent impacts resulting from vaccinations.”
Follow us on Google News and Twitter
For Latest IT Industry News, Follow us on Google News and Twitter